Akebia Therapeutics, Inc. (NASDAQ:AKBA) has earned an average recommendation of “Buy” from the nine analysts that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $19.50.

A number of analysts have weighed in on the stock. UBS AG restated a “buy” rating and set a $17.00 price objective (up from $12.00) on shares of Akebia Therapeutics in a research note on Friday, May 5th. HC Wainwright restated a “buy” rating and set a $24.00 price objective on shares of Akebia Therapeutics in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. BidaskClub upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Finally, ValuEngine upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd.

In other news, SVP Michel Dahan sold 5,000 shares of Akebia Therapeutics stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $15.00, for a total value of $75,000.00. Following the completion of the sale, the senior vice president now directly owns 102,224 shares in the company, valued at $1,533,360. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Muneer A. Satter purchased 1,034,482 shares of Akebia Therapeutics stock in a transaction dated Wednesday, July 5th. The stock was bought at an average price of $14.50 per share, with a total value of $14,999,989.00. The disclosure for this purchase can be found here. Insiders sold 7,544 shares of company stock valued at $111,287 over the last quarter. Company insiders own 8.67% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Eagle Asset Management Inc. raised its stake in shares of Akebia Therapeutics by 1.5% in the first quarter. Eagle Asset Management Inc. now owns 3,550,547 shares of the biopharmaceutical company’s stock worth $32,665,000 after buying an additional 51,190 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Akebia Therapeutics by 10.3% in the second quarter. Vanguard Group Inc. now owns 1,436,163 shares of the biopharmaceutical company’s stock valued at $20,638,000 after buying an additional 134,283 shares during the period. First Manhattan Co. raised its stake in shares of Akebia Therapeutics by 14.4% in the second quarter. First Manhattan Co. now owns 1,188,500 shares of the biopharmaceutical company’s stock valued at $17,078,000 after buying an additional 150,000 shares during the period. FMR LLC raised its stake in shares of Akebia Therapeutics by 11.3% in the second quarter. FMR LLC now owns 1,036,955 shares of the biopharmaceutical company’s stock valued at $14,901,000 after buying an additional 105,100 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Akebia Therapeutics by 165.4% in the second quarter. Renaissance Technologies LLC now owns 1,025,300 shares of the biopharmaceutical company’s stock valued at $14,734,000 after buying an additional 639,033 shares during the period. Hedge funds and other institutional investors own 57.62% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/29/akebia-therapeutics-inc-akba-given-consensus-rating-of-buy-by-analysts.html.

Akebia Therapeutics (NASDAQ AKBA) traded up 0.24% during trading on Tuesday, reaching $16.84. The company’s stock had a trading volume of 86,621 shares. The company’s market cap is $308.17 million. The stock’s 50-day moving average is $14.10 and its 200 day moving average is $12.26. Akebia Therapeutics has a 12 month low of $7.16 and a 12 month high of $16.95.

Akebia Therapeutics (NASDAQ:AKBA) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.36. The firm had revenue of $28.52 million for the quarter, compared to the consensus estimate of $26.50 million. On average, equities analysts forecast that Akebia Therapeutics will post ($2.82) EPS for the current fiscal year.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.